+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience



Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience



Head & Neck 32(5): 599-606



We retrospectively examined the treatment efficacy and toxicity profile of intensity-modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC). A total of 57 patients with stage III or IV HNSCC were treated with IMRT and concurrent weekly cisplatin (dosed at 30 mg/m(2)) between November 2001 and May 2007. The median prescription dose to the gross tumor volume was 70 Gy (using 2.0-2.2 Gy daily fractions). In-field tumor control at 2 years was 89.1%, locoregional control was 85.5%, and overall survival was 86.9%. The median radiation dose delivered was 70 Gy. The mean dose intensity of cisplatin administered was 25.7 mg/m(2)/week. Comprehensive head and neck IMRT to 70 Gy delivered with weekly cisplatin chemotherapy (30 mg/m(2)) is feasible and generally well tolerated.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269611

Download citation: RISBibTeXText

PMID: 19757422

DOI: 10.1002/hed.21224


Related references

Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience. Asian Pacific Journal of Cancer Prevention 12(5): 1185-1188, 2011

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget 7(43): 70185-70193, 2016

Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Annals of Oncology 10(6): 693-700, 1999

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis. Medicine 97(21): E10778, 2018

Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncology 48(3): 266-271, 2012

IMRT for head and neck cancer: The University of Arkansas experience. International Journal of Radiation Oncology*biology*physics 60: S521-S522, 2004

Long term results of comparison of concurrent low-dose daily cisplatin versus the standard weekly cisplatin with six fractions per week radiotherapy in locally advanced head neck cancer. South Asian Journal of Cancer 5(2): 80-84, 2016

Outpatient chemo-radiotherapy for locally advanced head and neck cancer using weekly cisplatin. British Journal of Cancer 88(Suppl. 1): S24, 2003

Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Onkologie 18(Suppl. 2): 93, 1995

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Head and Neck 32(2): 235-243, 2010

Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 116(19): 4533-4540, 2010

Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head & Neck 27(1): 36-43, 2004

Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. Oncologist 22(9): 1056-1066, 2017

Definitive altered fractionation radiotherapy and concomitant weekly cisplatin for locally advanced head and neck cancer. American Journal of Clinical Oncology 32(5): 488-491, 2009

Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncology 51(7): 704-708, 2015